Peter Reaven, MD

Personal Info

Dr. Reaven has a strong and broad clinical and research background in insulin resistance, diabetes, dyslipidemia and vascular disease, where he has pursued these related lines of investigation with multiple approaches, including in vitro studies, animal models, and carefully controlled intervention trials in clinical research center settings. During the past two decades, Dr. Reaven has been closely involved in the development, conduct and analysis of large, multicenter clinical trials and in utilizing these studies for identification of standard and novel risk factors for cardiovascular disease. Dr. Reaven is currently Co-chair, Executive Committee Member and site P.I. for the Veterans Administration Glycemic Control and Complications in Type 2 Diabetes Mellitus Trial Follow-up Study, site P.I. for Investigation of Metformin in Pre-Diabetes on Atherosclerotic Cardiovascular Outcomes and P.I. of the NIH funded Post-translational apolipoprotein C-III modifications and cardiovascular risk in Type 2 diabetes. Dr. Reaven is also a co-investigator on several VA MVP projects which utilize the extremely large VA EMR system to examine for phenotypic and genetic associations with diabetes and its many complications. An additional focus of Dr. Reaven’s work is on the development and testing of new formulations of diabetes drugs and the identification of opportunities and barriers to their use.